rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

These data add further evidence of rVSV-ZEBOV safety and immunogenicity, including in people with pre-existing antibodies from suspected natural ZEBOV infection whose state does not blunt rVSV-ZEBOV immune response. Pre-vaccination serological screening is not required.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2024-11-07
DOI
https://doi.org/10.1186/s12916-024-03726-z
Citations
2
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
0.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

Aminata Bagayoko, Séverine Danmadji Nadlaou, Mamadou Camara, Conall H. Watson et al.
2 citations
BMC Medicine
Viral Infections and Outbreaks Research
0.78
article

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

Aminata Bagayoko, Séverine Danmadji Nadlaou, Mamadou Camara, Conall H. Watson, Sophie Duraffour, Tom Tipton, Anton Camacho, Kalidou Toure, Rosalind M. Eggo, Yper Hall, Michael Marks, Andrea Vicari, Stephan Günther, Ana María Henao-Restrepo, Pierre‐Stéphane Gsell, Kékoura Ifono, Ibrahima Kaba, Sakoba Keïta, Miles W. Carroll, Ximena Riveros, Chrissy h. Roberts, Thierno Oumar Fofana, Mohamed Diaby, Thomas Strecker, André Maomou, Lansana Sylla, Cece Francis Kolié, Philos P. Damey, Honora A. Djidonou, Doussou Condé, Abdourahamane Diallo, Godwin Enwere, W. John Edmunds, Alhassane Touré, Fatoumata Diallo, Ismaila M. Sani, Kassié Doré
article en
2 citations

Abstract

These data add further evidence of rVSV-ZEBOV safety and immunogenicity, including in people with pre-existing antibodies from suspected natural ZEBOV infection whose state does not blunt rVSV-ZEBOV immune response. Pre-vaccination serological screening is not required.

BMC MedicineVol. 22(1)
University of Oxford (GB), London School of Hygiene & Tropical Medicine (GB), World Health Organization (CH), Epicentre (South Africa) (ZA), Philips (Germany) (DE), Ministry of Health and Public Hygiene (GN), UK Health Security Agency (GB), Bernhard Nocht Institute for Tropical Medicine (DE)
World Health Organization, United Nations Foundation, National Institute for Health and Care Research, Directorate-General for Development and Cooperation - EuropeAid
Good health and well-being
Openalex Percentile: Top 27%
Viral Infections and Outbreaks Research
0.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.